Long- Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)

Authors
Category Primary study
JournalArthritis Rheum
Year 2013
This article has no abstract
Epistemonikos ID: a5fde2e4378c812e8f699a59a555886059a5d25e
First added on: May 19, 2017